Duvelisib Drug Succeeds in Late-Stage Trial

I subscribe to Newsmax Health, and this was just released. I've seen this 'in trial' drug mentioned recently for CLL, and this looks like a promising new drug option. The manufacturer is going to submit the drug next year for approval.

Here is a paragraph from the writeup:

"Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's Arzerra (ofatumumab), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."

The link to the article:

newsmax.com/Health/Health-N...

oldestnewest

    You may also like...